Logo image of MNKD

MANNKIND CORP (MNKD) Stock Fundamental Analysis

NASDAQ:MNKD - Nasdaq - US56400P7069 - Common Stock - Currency: USD

4.56  +0.12 (+2.7%)

Fundamental Rating

5

Overall MNKD gets a fundamental rating of 5 out of 10. We evaluated MNKD against 568 industry peers in the Biotechnology industry. MNKD has an average financial health and profitability rating. MNKD is growing strongly while it is still valued neutral. This is a good combination!


Dividend Valuation Growth Profitability Health

Quickly go to:

5

1. Profitability

1.1 Basic Checks

MNKD had positive earnings in the past year.
In the past year MNKD had a positive cash flow from operations.
In the past 5 years MNKD reported 4 times negative net income.
The reported operating cash flow has been mixed in the past 5 years: MNKD reported negative operating cash flow in multiple years.
MNKD Yearly Net Income VS EBIT VS OCF VS FCFMNKD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M -200M -300M

1.2 Ratios

Looking at the Return On Assets, with a value of 7.00%, MNKD belongs to the top of the industry, outperforming 94.72% of the companies in the same industry.
MNKD has a better Return On Invested Capital (20.74%) than 98.24% of its industry peers.
Industry RankSector Rank
ROA 7%
ROE N/A
ROIC 20.74%
ROA(3y)-8.37%
ROA(5y)-20.59%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
MNKD Yearly ROA, ROE, ROICMNKD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100 -100 -200

1.3 Margins

With an excellent Profit Margin value of 9.66%, MNKD belongs to the best of the industry, outperforming 93.66% of the companies in the same industry.
Looking at the Operating Margin, with a value of 25.07%, MNKD belongs to the top of the industry, outperforming 96.83% of the companies in the same industry.
Looking at the Gross Margin, with a value of 74.19%, MNKD belongs to the top of the industry, outperforming 82.92% of the companies in the same industry.
MNKD's Gross Margin has improved in the last couple of years.
Industry RankSector Rank
OM 25.07%
PM (TTM) 9.66%
GM 74.19%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y13.44%
GM growth 5Y5.99%
MNKD Yearly Profit, Operating, Gross MarginsMNKD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600 -800 -1K

More info and screens

4

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so MNKD is creating value.
The number of shares outstanding for MNKD has been increased compared to 1 year ago.
The number of shares outstanding for MNKD has been increased compared to 5 years ago.
The debt/assets ratio for MNKD has been reduced compared to a year ago.
MNKD Yearly Shares OutstandingMNKD Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M
MNKD Yearly Total Debt VS Total AssetsMNKD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

2.2 Solvency

Based on the Altman-Z score of -7.78, we must say that MNKD is in the distress zone and has some risk of bankruptcy.
MNKD's Altman-Z score of -7.78 is on the low side compared to the rest of the industry. MNKD is outperformed by 68.84% of its industry peers.
The Debt to FCF ratio of MNKD is 8.83, which is on the high side as it means it would take MNKD, 8.83 years of fcf income to pay off all of its debts.
MNKD has a Debt to FCF ratio of 8.83. This is amongst the best in the industry. MNKD outperforms 92.96% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 8.83
Altman-Z -7.78
ROIC/WACC2.08
WACC9.98%
MNKD Yearly LT Debt VS Equity VS FCFMNKD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M

2.3 Liquidity

MNKD has a Current Ratio of 3.28. This indicates that MNKD is financially healthy and has no problem in meeting its short term obligations.
With a Current ratio value of 3.28, MNKD is not doing good in the industry: 62.50% of the companies in the same industry are doing better.
A Quick Ratio of 2.94 indicates that MNKD has no problem at all paying its short term obligations.
MNKD has a worse Quick ratio (2.94) than 63.91% of its industry peers.
Industry RankSector Rank
Current Ratio 3.28
Quick Ratio 2.94
MNKD Yearly Current Assets VS Current LiabilitesMNKD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

7

3. Growth

3.1 Past

MNKD shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 260.00%, which is quite impressive.
Looking at the last year, MNKD shows a very strong growth in Revenue. The Revenue has grown by 43.49%.
Measured over the past years, MNKD shows a very strong growth in Revenue. The Revenue has been growing by 35.29% on average per year.
EPS 1Y (TTM)260%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%390.38%
Revenue 1Y (TTM)43.49%
Revenue growth 3Y55.86%
Revenue growth 5Y35.29%
Sales Q2Q%31.3%

3.2 Future

The Earnings Per Share is expected to grow by 43.66% on average over the next years. This is a very strong growth
MNKD is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 14.37% yearly.
EPS Next Y133.15%
EPS Next 2Y82.07%
EPS Next 3Y58.67%
EPS Next 5Y43.66%
Revenue Next Year13.64%
Revenue Next 2Y14.1%
Revenue Next 3Y12.72%
Revenue Next 5Y14.37%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
MNKD Yearly Revenue VS EstimatesMNKD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 200M 400M 600M 800M
MNKD Yearly EPS VS EstimatesMNKD Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -1 -2

More info and screens

6

4. Valuation

4.1 Price/Earnings Ratio

MNKD is valuated quite expensively with a Price/Earnings ratio of 57.00.
92.96% of the companies in the same industry are more expensive than MNKD, based on the Price/Earnings ratio.
The average S&P500 Price/Earnings ratio is at 27.63. MNKD is valued rather expensively when compared to this.
With a Price/Forward Earnings ratio of 24.45, MNKD is valued on the expensive side.
93.31% of the companies in the same industry are more expensive than MNKD, based on the Price/Forward Earnings ratio.
When comparing the Price/Forward Earnings ratio of MNKD to the average of the S&P500 Index (20.85), we can say MNKD is valued inline with the index average.
Industry RankSector Rank
PE 57
Fwd PE 24.45
MNKD Price Earnings VS Forward Price EarningsMNKD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60 80

4.2 Price Multiples

Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of MNKD indicates a rather cheap valuation: MNKD is cheaper than 95.07% of the companies listed in the same industry.
94.01% of the companies in the same industry are more expensive than MNKD, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 42.22
EV/EBITDA 16.35
MNKD Per share dataMNKD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4 0.6 0.8

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
MNKD's earnings are expected to grow with 58.67% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.43
PEG (5Y)N/A
EPS Next 2Y82.07%
EPS Next 3Y58.67%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for MNKD!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MANNKIND CORP

NASDAQ:MNKD (4/22/2025, 12:25:01 PM)

4.56

+0.12 (+2.7%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-26 2025-02-26/amc
Earnings (Next)05-07 2025-05-07/amc
Inst Owners61.62%
Inst Owner Change0.11%
Ins Owners1.42%
Ins Owner Change1.03%
Market Cap1.39B
Analysts86.67
Price Target10.2 (123.68%)
Short Float %9.78%
Short Ratio13.99
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-26.47%
Min EPS beat(2)-34.64%
Max EPS beat(2)-18.3%
EPS beat(4)1
Avg EPS beat(4)-62.27%
Min EPS beat(4)-246.98%
Max EPS beat(4)50.83%
EPS beat(8)4
Avg EPS beat(8)-14.92%
EPS beat(12)5
Avg EPS beat(12)-9.48%
EPS beat(16)6
Avg EPS beat(16)-8.92%
Revenue beat(2)1
Avg Revenue beat(2)-3.7%
Min Revenue beat(2)-7.78%
Max Revenue beat(2)0.38%
Revenue beat(4)3
Avg Revenue beat(4)2.37%
Min Revenue beat(4)-7.78%
Max Revenue beat(4)9.49%
Revenue beat(8)6
Avg Revenue beat(8)4.13%
Revenue beat(12)9
Avg Revenue beat(12)7.39%
Revenue beat(16)12
Avg Revenue beat(16)6.84%
PT rev (1m)0%
PT rev (3m)6.19%
EPS NQ rev (1m)-2.22%
EPS NQ rev (3m)46.67%
EPS NY rev (1m)-25.36%
EPS NY rev (3m)-16.88%
Revenue NQ rev (1m)-0.24%
Revenue NQ rev (3m)4.15%
Revenue NY rev (1m)-0.38%
Revenue NY rev (3m)-3.23%
Valuation
Industry RankSector Rank
PE 57
Fwd PE 24.45
P/S 4.85
P/FCF 42.22
P/OCF 32.59
P/B N/A
P/tB N/A
EV/EBITDA 16.35
EPS(TTM)0.08
EY1.75%
EPS(NY)0.19
Fwd EY4.09%
FCF(TTM)0.11
FCFY2.37%
OCF(TTM)0.14
OCFY3.07%
SpS0.94
BVpS-0.26
TBVpS-0.28
PEG (NY)0.43
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 7%
ROE N/A
ROCE 22.94%
ROIC 20.74%
ROICexc 56.39%
ROICexgc 60.16%
OM 25.07%
PM (TTM) 9.66%
GM 74.19%
FCFM 11.49%
ROA(3y)-8.37%
ROA(5y)-20.59%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y13.44%
GM growth 5Y5.99%
F-Score8
Asset Turnover0.72
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 8.83
Debt/EBITDA 3.39
Cap/Depr 131.5%
Cap/Sales 3.4%
Interest Coverage 4.09
Cash Conversion 53.84%
Profit Quality 118.96%
Current Ratio 3.28
Quick Ratio 2.94
Altman-Z -7.78
F-Score8
WACC9.98%
ROIC/WACC2.08
Cap/Depr(3y)397.13%
Cap/Depr(5y)337.1%
Cap/Sales(3y)10.78%
Cap/Sales(5y)10.98%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)260%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%390.38%
EPS Next Y133.15%
EPS Next 2Y82.07%
EPS Next 3Y58.67%
EPS Next 5Y43.66%
Revenue 1Y (TTM)43.49%
Revenue growth 3Y55.86%
Revenue growth 5Y35.29%
Sales Q2Q%31.3%
Revenue Next Year13.64%
Revenue Next 2Y14.1%
Revenue Next 3Y12.72%
Revenue Next 5Y14.37%
EBIT growth 1Y573.12%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y493.17%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y24.69%
OCF growth 3YN/A
OCF growth 5YN/A